Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New rabies shot shows promise in preventing deadly infection after bites

NCT ID NCT03961555

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study tested a new medicine called SYN023 to prevent rabies in people who were bitten or scratched by animals like dogs or bats. About 448 adults with different levels of rabies risk received either SYN023 or the standard rabies immune globulin, along with the rabies vaccine. The goal was to see if SYN023 works as well as the current treatment to stop rabies from developing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

448 people

The number who actually took part.

Started

Sep 2019

Finished

Dec 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (Low Risk Group): Subjects must meet all of the following criteria at the time of subject ID assignment: 1. History of dog, cat, mongoose, fox, ferret, skunk, bat or raccoon bite to trunk, leg, ankle or foot, or lick or scratch with, or of broken skin or mucous membrane saliva or neural tissue contamination, unprotected physical bat contact, scratch or saliva contamination of the head or neck without broken skin all ≤ 54 hours 2. Has completed the written informed consent process and signed informed consent document 3. Males and females 4. Is age equal or more than 18 years on Study Day 1 5. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study 6. Lives within 2 hour journey by available transportation to study center 7. For female subjects: agrees to avoid pregnancy from Study Day 1 through Study Day 121. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide Inclusion Criteria (Normal Risk Group) Subjects must meet all of the following criteria at the time of subject ID assignment: 1. History of dog, cat, mongoose, fox, ferret, skunk, bat or raccoon bite to any body part, lick or scratch with, or of broken skin, mucous membrane saliva or neural tissue contamination, or unprotected physical bat contact all ≤ 54 hours from post exposure prophylaxis (PEP) 2. Has completed the written informed consent process and signed informed consent document. 3. Males and females 4. Is age equal or more than 18 years on Study Day 1 5. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study 6. Lives within 2 hour journey by available transportation to study center 7. For female subjects: agrees to avoid pregnancy from agrees to avoid pregnancy from Study Day 1 through Study Day 121. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide Exclusion Criteria: Subjects must have had none of the following at the time of subject ID assignment: 1. Clinical evidence of rabies infection 2. Category 3 exposure \> 54 hours before Study Drug receipt 3. History or serological evidence of previous rabies vaccination 4. Previous receipt of equine or human rabies globulin 5. History of hypersensitivity reaction to equine or human immunoglobulin. 6. Received immunoglobulin or blood products within 42 days before Study Day 1 7. Received any investigational drug therapy or investigational vaccine within 60 days before Study Day 1 8. Planned participation in any other investigational study during the study period. 9. Receiving systemic immunosuppressant medication such as systemic corticosteroids but not limited to systemic corticosteroids 10. History or laboratory evidence of any past, present, or possible immunodeficiency state including but not limited to any laboratory indication of HIV infection 11. Previous medical history that may compromise the safety of the subject in the study according to the opinion of the principal investigator 12. History or evidence on physical examination of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or activity of SYN023 13. Pregnancy (results of the urine pregnancy test MUST be known before enrollment)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rabies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Asian Hospital and Medical Center

    Muntinlupa, National Capital Region, 1780, Philippines

  • Baguio General Hospital and Medical Center

    Baguio City, Benguet, 2600, Philippines

  • Center of Excellence in Drug Research, Evaluation and Studies, Inc.

    Muntinlupa, National Capital Region, 1781, Philippines

  • Clinical Research Solutions PC -Milan

    Milan, Tennessee, 38358, United States

  • De La Salle Health Sciences Institute Independent Ethics Committee

    Cavite City, Calabarzon, 4114, Philippines

  • Far Eastern University Hospital Nicanor Reyes Medical Foundation

    Quezon City, National Capital Region, 1118, Philippines

  • Manila Doctors Hospital Institutional Review Board

    Manila, National Capital Region, 1000, Philippines

  • Mary Johnston Hospital

    Manila, Philippines

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Research Institute For Tropical Medicine

    Muntinlupa, National Capital Region, 1781, Philippines

  • Southern Philippines Medical Center

    Davao City, Davao (Region XI), 8000, Philippines

  • University of Florida

    Gainesville, Florida, 32610, United States

  • University of Iowa

    Iowa City, Iowa, 52242, United States

  • University of Virginia

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.